Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
          Improved Exercise
          Capacity
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Improved Exercise Capacity

AIR Pivotal Trial: Randomized, double-blind, multicenter, placebo-controlled trial to evaluate the efficacy and safety of Ventavis Inhalation Solution compared to placebo in the treatment of pulmonary arterial hypertension (PAH seen at 30 min post-inhalation)

  • At week 12, there was a 40-meter difference between Ventavis and placebo (change from baseline in 6-minute distance measured 30 min post-inhalation; p <0.01)1
  • When measured immediately prior to inhalation, the improvement compared to placebo was approximately 60% of the effect seen at 30 min post-inhalation1

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2010.



* In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

IMPORTANT SAFETY INFORMATION:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).

Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

ACTELION